Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Carmat stock

ALCAR.PA
FR0010907956
A1C017

Price

1.09
Today +/-
-0.01
Today %
-0.92 %

Carmat stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Carmat stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Carmat stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Carmat stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Carmat's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Carmat Stock Price History

DateCarmat Price
1/14/20251.09 undefined
1/14/20251.10 undefined
1/13/20251.06 undefined
1/10/20251.10 undefined
1/9/20251.06 undefined
1/8/20251.07 undefined
1/7/20251.03 undefined
1/6/20251.08 undefined
1/3/20251.21 undefined
1/2/20251.12 undefined
12/31/20241.09 undefined
12/30/20241.04 undefined
12/27/20241.04 undefined
12/24/20241.06 undefined
12/23/20241.05 undefined
12/20/20240.97 undefined
12/19/20241.00 undefined
12/18/20241.00 undefined
12/17/20241.01 undefined

Carmat Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Carmat, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Carmat from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Carmat’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Carmat. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Carmat’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Carmat’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Carmat’s growth potential.

Carmat Revenue, EBIT and net profit per share

DateCarmat RevenueCarmat EBITCarmat Net Income
2027e293.27 M undefined62.36 M undefined39.71 M undefined
2026e51.68 M undefined-36.02 M undefined-22.27 M undefined
2025e22.52 M undefined-41.02 M undefined-33.74 M undefined
2024e10.54 M undefined-47.95 M undefined-56.69 M undefined
20232.8 M undefined-52.52 M undefined-53.87 M undefined
2022345,000 undefined-51.99 M undefined-53.68 M undefined
20212.23 M undefined-60.41 M undefined-61.87 M undefined
20200 undefined-36.41 M undefined-36.96 M undefined
20190 undefined-42.48 M undefined-42.65 M undefined
20180 undefined-42.77 M undefined-41.73 M undefined
20170 undefined-31.03 M undefined-29.23 M undefined
20160 undefined-24.58 M undefined-22.98 M undefined
20150 undefined-19.77 M undefined-17.55 M undefined
20140 undefined-19.87 M undefined-18.26 M undefined
20130 undefined-16.12 M undefined-14.64 M undefined
20120 undefined-22.39 M undefined-17.19 M undefined
20110 undefined-16.09 M undefined-13.44 M undefined
20100 undefined-10.49 M undefined-7.74 M undefined
20090 undefined-5.98 M undefined-4.72 M undefined

Carmat Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e
000000000000202102251293
---------------400.00120.00131.82474.51
-------------2,000.00--1,550.00-310.00-140.91-60.78-10.58
-7-11-16-16-13-14-13-17-21-30-28-24-40-28-310000
-4-7-13-17-14-18-17-22-29-41-42-36-61-53-53-56-33-2239
-75.0085.7130.77-17.6528.57-5.5629.4131.8241.382.44-14.2969.44-13.11-5.66-41.07-33.33-277.27
2.882.884.134.144.284.384.516.039.019.279.279.2715.5722.6824.790000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Carmat Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Carmat is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200920102011201220132014201520162017201820192020202120222023
                             
0.7111.4229.3711.1316.889.223.0131.1660.7225.355.5135.9839.1951.438.01
0000000000004641400
0000000000003.373.520
000000000009.914.3417.4423.94
0.220.350.790.20.520.340.370.350.550.810.622.864.315.285.33
0.9311.7730.1611.3317.49.563.3931.5161.2726.1156.1248.7561.6877.837.29
2.732.832.451.560.950.670.621.234.215.565.116.416.786.79.95
80430470540560454.58377.97322472.54485.88473.5545.53533737613
0000000000003.363.520
430320230170130253.6217.61196.4972.0789.7827.7217.088800
000000000000000
0000000000001-171
3.243.583.152.271.641.381.221.754.756.145.616.9810.7610.9610.64
4.1715.3533.3113.619.0410.944.633.2666.0232.2561.7355.7372.4488.7647.92
                             
90150170170170175.2183.12241.28360.66371.04504.39520.5623907992
8.1625.7852.6352.8664.7970.8282132.11189.54194.56254.0529.784.6169.739.04
-4.72-12.46-25.9-43.09-57.73-76-93.54-116.52-145.75-187.45-230.09-36.91-98.78-68.82-54.99
00000012.7713.0613.0613.0614.5114.5114.5114.6618.02
000000000000000
3.5313.4726.99.947.23-51.428.8957.2120.5438.977.820.9616.48-26.94
0.924.194.994.014.793.153.013.595.837.625.358.018.396.539.61
0.510.831.161.311.471.61.711.612.122.933.224.385.185.75.93
01101000022.260099.4831.7231.725618
530330380150200000000000
00000000000002.640
1.965.466.545.476.284.754.745.27.9410.658.612.4213.5714.8815.55
0.010.080.220.460.821.352.223.213.714.6516.4138.9452.0255.3657.65
000000000000000
0.552.043.783.827.6612.950.280.190.980.990.690.662.531.176.8
0.562.1244.288.4814.292.53.414.75.6417.139.654.5556.5364.45
2.527.5810.549.7514.7619.047.258.612.6416.2925.752.0268.1271.480.01
6.0521.0537.4419.6921.9914.048.6537.4969.8536.8364.6859.8469.0887.8853.07
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Carmat provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Carmat's financial health and stability.

Assets

Carmat's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Carmat must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Carmat after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Carmat's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20092010201120122013201420152016201720182019202020212022
-4-7-13-17-14-18-17-22-29-41-42-36-60-51
0111100011181510
00000000000000
002-23-100210-17-10-3
000000000012-5-9
00000000000000
00000000000000
-4-6-9-17-9-18-17-21-24-38-40-43-60-54
-2-1-10000-1-3-20-2-1-1
-2-1-10000-1-3-20-2-1-1
00000000000000
00000000000000
0310300000112090
0000000000005469
7192801511115057571256568
715260116115057559500
00000000000000
01017-185-7-62829-3530-19312
-7.06-8.17-10.59-18.4-9.91-19.08-17.48-22.37-27.84-40.47-40.89-45.36-61.92-56.36
00000000000000

Carmat stock margins

The Carmat margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Carmat. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Carmat.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Carmat's sales revenue. A higher gross margin percentage indicates that the Carmat retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Carmat's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Carmat's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Carmat's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Carmat. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Carmat's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Carmat Margin History

Carmat Gross marginCarmat Profit marginCarmat EBIT marginCarmat Profit margin
2027e-1,109.12 %21.26 %13.54 %
2026e-1,109.12 %-69.69 %-43.09 %
2025e-1,109.12 %-182.17 %-149.83 %
2024e-1,109.12 %-454.81 %-537.62 %
2023-1,109.12 %-1,877.8 %-1,925.96 %
2022-8,253.33 %-15,069.28 %-15,559.71 %
2021-1,822.3 %-2,710.09 %-2,775.82 %
2020-1,109.12 %0 %0 %
2019-1,109.12 %0 %0 %
2018-1,109.12 %0 %0 %
2017-1,109.12 %0 %0 %
2016-1,109.12 %0 %0 %
2015-1,109.12 %0 %0 %
2014-1,109.12 %0 %0 %
2013-1,109.12 %0 %0 %
2012-1,109.12 %0 %0 %
2011-1,109.12 %0 %0 %
2010-1,109.12 %0 %0 %
2009-1,109.12 %0 %0 %

Carmat Stock Sales Revenue, EBIT, Earnings per Share

The Carmat earnings per share therefore indicates how much revenue Carmat has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Carmat earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Carmat's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Carmat’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Carmat's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Carmat Revenue, EBIT and net profit per share

DateCarmat Sales per ShareCarmat EBIT per shareCarmat Earnings per Share
2027e6.92 undefined0 undefined0.94 undefined
2026e1.22 undefined0 undefined-0.53 undefined
2025e0.53 undefined0 undefined-0.8 undefined
2024e0.25 undefined0 undefined-1.34 undefined
20230.11 undefined-2.12 undefined-2.17 undefined
20220.02 undefined-2.29 undefined-2.37 undefined
20210.14 undefined-3.88 undefined-3.97 undefined
20200 undefined-3.93 undefined-3.99 undefined
20190 undefined-4.58 undefined-4.6 undefined
20180 undefined-4.61 undefined-4.5 undefined
20170 undefined-3.44 undefined-3.24 undefined
20160 undefined-4.08 undefined-3.81 undefined
20150 undefined-4.38 undefined-3.89 undefined
20140 undefined-4.54 undefined-4.17 undefined
20130 undefined-3.77 undefined-3.42 undefined
20120 undefined-5.41 undefined-4.15 undefined
20110 undefined-3.9 undefined-3.25 undefined
20100 undefined-3.64 undefined-2.69 undefined
20090 undefined-2.08 undefined-1.64 undefined

Carmat business model

Carmat SA is a French company that was founded in 2008 and is headquartered in Vélizy-Villacoublay, France. The company is involved in the development, manufacture, and sale of cardiovascular systems and artificial hearts. Carmat is a leader in developing technologies for the treatment of serious heart conditions and aims to provide highly innovative solutions for patients suffering from end-stage heart failure. The business model of Carmat is based on the development and commercialization of products that contribute to improving the quality of life for patients with serious heart conditions. The artificial hearts are made from biocompatible materials and can be implanted in human bodies. They can serve as a bridge to a heart transplant or even as a permanent solution for complete replacement of the natural heart. Carmat is divided into various divisions including research and development, production, sales, and marketing. The company's research and development department works on developing highly specialized technologies for the artificial hearts to enhance performance and reliability. The production department manufactures the artificial hearts and ensures a strictly controlled, sterile environment to ensure the highest quality of products. The sales and marketing team ensures that the artificial hearts are marketed and sold worldwide. Carmat currently offers the Carmat heart, which is considered a revolutionary product in the market. The heart is made from biocompatible materials and is produced through a strictly controlled process. It has been designed to maximize performance and reliability in an artificial heart solution. The artificial hearts are implanted in an elaborate and fully equipped operating room to ensure an optimal environment. Carmat has also formed partnerships with other companies and institutions to strengthen its research and development department and share knowledge and experience in the industry. This includes a partnership with Airbus, which supports the company in developing new technologies. Carmat also collaborates with medical facilities to test the artificial hearts and improve their performance. Overall, Carmat is a leading brand in the field of artificial hearts. The company aims to develop innovative products to improve the lives of people with heart failure. It has established itself as a reliable provider of artificial hearts in the market and strives to constantly improve its business activities to meet the growing demand for more effective treatment options for patients with heart problems. Carmat is one of the most popular companies on Eulerpool.com.

Carmat SWOT Analysis

Strengths

Carmat SA possesses several strengths that contribute to its competitive advantage and market positioning. These strengths include:

  • Advanced Technology: Carmat SA is a pioneer in the development of artificial hearts, utilizing innovative technology to provide life-saving solutions for patients with end-stage heart failure.
  • Strong Intellectual Property: The company holds a significant portfolio of patents and intellectual property rights, which serves as a barrier to entry for potential competitors.
  • Strategic Partnerships: Carmat has established partnerships with leading research institutions and medical centers, fostering collaboration and driving advancements in its technology.
  • Experienced Management Team: The company is led by a team of experienced professionals with a deep understanding of the industry and a track record of successful commercialization.

Weaknesses

Although Carmat SA has several strengths, it also faces certain weaknesses that may hinder its growth and performance. These weaknesses include:

  • High Production Costs: The manufacturing process for artificial hearts is complex and expensive, resulting in high production costs and a potential barrier to affordability for patients and healthcare systems.
  • Regulatory Challenges: The medical device industry is subject to stringent regulatory requirements, which may delay product approvals and market entry for Carmat SA.
  • Limited Market Acceptance: The adoption of artificial hearts by healthcare providers and patients may be slow due to concerns regarding efficacy, long-term outcomes, and patient acceptance.

Opportunities

Carmat SA can leverage various opportunities to enhance its growth prospects and market expansion. These opportunities include:

  • Increasing Incidence of Heart Failure: The rising prevalence of heart failure worldwide creates a significant market opportunity for Carmat SA, as its artificial heart technology offers potential solutions for patients who are ineligible for heart transplants.
  • Partnering with Hospitals and Clinics: Collaborating with renowned healthcare providers could strengthen Carmat's market presence and facilitate the adoption of its technology, as well as provide valuable feedback for product improvement.
  • Geographical Expansion: Exploring new markets and expanding into different regions can help Carmat SA diversify its revenue streams and reduce dependency on specific markets.

Threats

Carmat SA faces various threats that could impact its business operations and future growth. These threats include:

  • Competition from Established Device Manufacturers: Established medical device manufacturers may enter the artificial heart market with competing products, posing a threat to Carmat's market share.
  • Financial Constraints: Continued research and development efforts, along with the scale-up of manufacturing capabilities, require substantial financial resources, which may pose challenges if funding is insufficient.
  • Changing Regulatory Landscape: Evolving regulatory standards and requirements in the healthcare industry may necessitate substantial investments and modifications to Carmat's products and processes.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Carmat Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Carmat historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Carmat shares outstanding

The number of shares was Carmat in 2024 — This indicates how many shares 24.788 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Carmat earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Carmat's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Carmat’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Carmat's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Carmat.

Carmat shareholders

%
Name
Stocks
Change
Date
6.95036 % Bastid (Pierre)2,946,9541,041,66612/31/2023
6.29868 % Airbus SE2,670,640012/31/2023
5.93949 % Ligresti (Antonino)2,518,344694,44412/31/2023
2.07547 % Famille Gaspard880,000-230,00012/31/2023
1.60153 % Groupe Therabel679,050138,88812/31/2023
1.43062 % Carpentier (Alain)606,583-5,00012/31/2023
1.08188 % Cornovum458,715012/31/2023
0.44811 % Credit Mutuel Asset Management190,00006/30/2024
0.41077 % Piat (Stephane)174,16567,59412/31/2023
0.34111 % La Française AM144,631-55,3694/30/2024
1
2
3

Carmat Executives and Management Board

Mr. Stephane Piat

(51)
Carmat Chief Executive Officer, Director (since 2016)
Compensation 588,725

Mr. Pierre Bastid

(68)
Carmat Independent Director
Compensation 48,000

Mr. John Hernandez

(56)
Carmat Independent Director
Compensation 48,000

Dr. Michael Mack

(75)
Carmat Independent Director
Compensation 48,000

Dr. Antonino Ligresti

(84)
Carmat Independent Director - Representative of Sante Holdings SRL
Compensation 44,000
1
2
3
4

Carmat Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Edwards Lifesciences Stock
Edwards Lifesciences
SupplierCustomer0,060,250,430,360,01-0,09
Victrex Stock
Victrex
SupplierCustomer0,030,420,130,900,890,72
Airbus Stock
Airbus
SupplierCustomer-0,55-0,420,520,140,410,14
1

Most common questions regarding Carmat

What values and corporate philosophy does Carmat represent?

Carmat SA represents values of innovation, medical advancement, and patient care. With its corporate philosophy centered around improving the quality of life for individuals with end-stage heart failure, Carmat SA aims to provide a groundbreaking solution through its artificial heart technology. The company's relentless focus on research and development, collaboration with medical professionals, and commitment to excellence underscores its dedication to transforming the field of cardiac medicine. Carmat SA strives to enhance patients' well-being by offering a revolutionary cardiac solution that integrates seamlessly into their lives, emphasizing its commitment to both technological prowess and human compassion.

In which countries and regions is Carmat primarily present?

Carmat SA is primarily present in France and the European Union (EU) region.

What significant milestones has the company Carmat achieved?

Carmat SA, a leading biomedical company, has achieved several significant milestones. Firstly, the company successfully developed and received European approval for its cutting-edge biocompatible artificial heart (Aeson). This breakthrough medical device offers a potential life-saving solution for end-stage heart failure patients. Secondly, Carmat SA successfully performed clinical trials demonstrating the feasibility and safety of their artificial heart. Moreover, the company achieved the first human implantation of Aeson, which was an important milestone towards commercialization. These milestones highlight Carmat SA's commitment to innovative biomedical solutions and their pursuit of transforming the lives of patients suffering from heart failure.

What is the history and background of the company Carmat?

Carmat SA, a leading French biomedical company, has a significant history and background. Established in 2008, Carmat aims to revolutionize cardiac medicine through its cutting-edge technology. The company's flagship product, the Carmat Total Artificial Heart (TAH), is an innovative solution for patients with end-stage biventricular heart failure. Designed to mimic the natural heart, the TAH offers hope to individuals otherwise awaiting heart transplantation. Carmat SA combines expertise in biomechanics, robotics, and material science to develop this groundbreaking device. By addressing the global shortage of donor organs, Carmat SA strives to improve the quality of life for patients suffering from severe heart conditions.

Who are the main competitors of Carmat in the market?

The main competitors of Carmat SA in the market include companies such as Medtronic PLC, Abbott Laboratories, Edwards Lifesciences Corporation, and SynCardia Systems, LLC.

In which industries is Carmat primarily active?

Carmat SA is primarily active in the medical device industry.

What is the business model of Carmat?

The business model of Carmat SA is focused on the development and commercialization of innovative cardiovascular devices to address heart failure. Carmat SA has developed the world's most advanced total artificial heart (TAH), which aims to improve the prognosis and quality of life for patients suffering from end-stage biventricular heart failure. With its unique biocompatible design and integration of cutting-edge technologies, Carmat's TAH offers hope for patients awaiting heart transplantation. By combining expertise in biomedical engineering and cardiology, Carmat SA aims to revolutionize the field of heart failure treatment and provide long-term solutions for patients in need.

What is the P/E ratio of Carmat 2025?

The Carmat P/E ratio is -0.8.

What is the P/S ratio of Carmat 2025?

The Carmat P/S ratio is 1.2.

What is the Quality Investing of Carmat?

The Quality Investing for Carmat is 6/10.

What is the revenue of Carmat 2025?

The expected Carmat revenue is 22.52 M EUR.

How high is the profit of Carmat 2025?

The expected Carmat profit is -33.74 M EUR.

What is the business model of Carmat

Carmat SA is a French company specializing in the development, manufacturing, and marketing of innovative therapy products for patients with severe heart failure. The company is headquartered in Vélizy-Villacoublay, a municipality in the southwest of Paris, and is listed on the Euronext Paris stock exchange. Carmat SA's business model consists of three main areas: research and development, production, and distribution. In the research and development area, the company focuses on the exploration and development of implantable artificial hearts as an alternative to conventional treatment methods for end-stage heart failure patients. It aims to prolong the lives and improve the quality of life of patients. The production area of Carmat SA encompasses the manufacturing of implantable artificial hearts that adhere to the highest standards to ensure their suitability for human use. The company employs state-of-the-art manufacturing methods and materials. The production is a complex task due to the high quality requirements and compliance with medical technology regulations. Carmat SA's distribution area is focused on introducing the implantable artificial hearts in selected global markets. The company collaborates closely with medical institutions and networks to promote widespread acceptance of this innovation. Carmat SA has a clear vision for the development of artificial hearts that can enable patients with severe heart failure to lead independent lives. By integrating cutting-edge technology and innovative design features, the treatment of heart failure is intended to be revolutionized. Carmat SA aims to be a leading provider of medical technology for the cardiology industry. The artificial hearts developed by Carmat SA make a significant contribution to patients with severe heart failure. In addition to the development of high-quality heart supplementation solutions, the company also focuses on continuous improvement and adaptation of its products to meet the patients' needs. To ensure the quality and longevity of its products, Carmat SA invests heavily in research and development. The company collaborates with leading experts in the fields of medicine and technology to keep its products at the forefront of technological advancements. In summary, Carmat SA is an innovative company specializing in the development, manufacturing, and marketing of implantable artificial hearts for patients with heart failure. Through its research and development, production, and distribution areas, the company effectively produces and sells its products. Carmat SA aims to increase its market share in the medical technology industry for cardiology and contribute to improving the quality of life for patients with heart failure.

What is the Carmat dividend?

Carmat pays a dividend of 0 EUR distributed over payouts per year.

How often does Carmat pay dividends?

The dividend cannot currently be calculated for Carmat or the company does not pay out a dividend.

What is the Carmat ISIN?

The ISIN of Carmat is FR0010907956.

What is the Carmat WKN?

The WKN of Carmat is A1C017.

What is the Carmat ticker?

The ticker of Carmat is ALCAR.PA.

How much dividend does Carmat pay?

Over the past 12 months, Carmat paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Carmat is expected to pay a dividend of 0 EUR.

What is the dividend yield of Carmat?

The current dividend yield of Carmat is .

When does Carmat pay dividends?

Carmat pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Carmat?

Carmat paid dividends every year for the past 0 years.

What is the dividend of Carmat?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Carmat located?

Carmat is assigned to the 'Health' sector.

Wann musste ich die Aktien von Carmat kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Carmat from 1/15/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.

When did Carmat pay the last dividend?

The last dividend was paid out on 1/15/2025.

What was the dividend of Carmat in the year 2024?

In the year 2024, Carmat distributed 0 EUR as dividends.

In which currency does Carmat pay out the dividend?

The dividends of Carmat are distributed in EUR.

All fundamentals about Carmat

Our stock analysis for Carmat Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Carmat Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.